Balancing Risk And Speed When Time Is Of The Essence: Proven Strategies To Accelerate Drug Development

By Cyrielle Corbin, Ph.D., Nadia Oueslati, Ph.D., Cyril Rols, Jiangli Yan, Ph.D., Muriel Richard and Marie-Gaelle Rogers

For an early-stage biotech, the decisions made now will shape the future of the company and can determine long-term success or failure. From day one, the pressure is on to rapidly progress towards milestones and demonstrate value to investors and other stakeholders. You need to move quickly and use resources efficiently to advance a drug candidate into the clinic and ultimately onto the market.

Biotech companies are faced with making a strategic assessment of how best to balance speed and risk and the impact of that decision. An experienced contract development and manufacturing organization (CDMO) can help guide you through the different stages of drug development and identify opportunities to accelerate timelines while ensuring that risk is properly mitigated, and quality is not compromised. In this ebook, we describe four areas of development where we have applied this strategy for customers.